Advertisement
Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

10 Things You Might Not Know About Ebola

August 15, 2014 1:09 pm | by Christina Jakubowski, News Editor | News | Comments

The 2014 outbreak of Ebola virus in West Africa has the world on high alert. Currently deemed an international public health emergency by the WHO, the virus has racked up more than 1,060 deaths and sickened 1,975 – making it the deadliest Ebola outbreak ever.

TOPICS:

Mallinckrodt Acquires Questcor Pharmaceuticals

August 15, 2014 10:27 am | News | Comments

Mallinckrodt plc, a leading global specialty pharmaceutical company, announced that it has completed its acquisition of Questcor Pharmaceuticals Inc. in a cash and stock transaction valued at approximately $5.8 billion following strong approval by both Mallinckrodt and Questcor shareholders. Read more...

TOPICS:

FDA Accepts BLA for Meningococcal Vaccine

August 15, 2014 10:18 am | News | Comments

Pfizer Inc. announced that the U.S. Food and Drug Administration has accepted for review the Biologics License Application for bivalent recombinant LP2086, the company’s vaccine candidate for the prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroup B in 10 through 25 year olds. Read more...

TOPICS:
Advertisement

HIV Patients in Developing Countries Face New Health Threats

August 15, 2014 10:11 am | News | Comments

Health care systems that keep HIV patients from dying early in low- and middle-income nations need urgently to be repurposed to treat the chronic diseases that many of these patients now have, according to recommendations resulting from a multidisciplinary conference sponsored by the National Institutes of Health. Read more...

TOPICS:

FDA Approves Avastin in Cervical Cancer

August 15, 2014 10:00 am | News | Comments

Roche announced that the U.S. Food and Drug Administration (FDA) approved Avastin (bevacizumab) in combination with paclitaxel and cisplatin or paclitaxel and topotecan for the treatment of women with persistent, recurrent or metastatic carcinoma of the cervix. Read more...

TOPICS:

Chikungunya Vaccine Induces Robust Antibody Response

August 15, 2014 9:55 am | News | Comments

An experimental vaccine to prevent the mosquito-borne viral illness chikungunya elicited neutralizing antibodies in all 25 adult volunteers who participated in a recent early-stage clinical trial conducted by researchers at the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health. Read more...

TOPICS:

Unlocking the Power of Big Data in R&D, Part One

August 15, 2014 9:09 am | by Sharon Benzeno, PhD, MBA, Senior Director, Business Development Bioinformatics, Elsevier | Articles | Comments

Big data promises big insights for drug discovery and development, but its intrinsic value will be unlocked only if R&D organizations have the tools to make sense of it. Part 1 of this two-part article looks at how new models are changing the world of R&D. Read more...

TOPICS:

NSAIDs May Lower Breast Cancer Recurrence Rate

August 14, 2014 3:30 pm | News | Comments

Recurrence of hormone-related breast cancer was cut by half in overweight and obese women who regularly used aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs), according to new data. Read more...            

TOPICS:
Advertisement

Amgen Multiple Myeloma Drug Misses Phase 3 Endpoint

August 14, 2014 3:24 pm | News | Comments

Amgen and its subsidiary Onyx Pharmaceuticals Inc. announced that the Phase 3 clinical trial FOCUS did not meet its primary endpoint of improving overall survival (OS). Read more...                   

TOPICS:

Allergan Buys Bladder Treatment Program from TARIS Biomedical

August 14, 2014 3:17 pm | News | Comments

Allergan and TARIS Holdings announced that Allergan has closed a transaction to acquire worldwide rights to TARIS Biomedical's lead program, LiRIS, which is currently in Phase 2 trials for the treatment of interstitial cystitis/bladder pain syndrome (IC/BPS). Read more...

TOPICS:

Potential Drug Therapy for Kidney Stones Identified

August 14, 2014 3:10 pm | News | Comments

Anyone who has suffered from kidney stones is keenly aware of the lack of drugs to treat the condition, which often causes excruciating pain. Now, a new mouse study suggests that a class of drugs approved to treat leukemia and epilepsy also may be effective against kidney stones, researchers report. Read more...

TOPICS:

Injection of Modified Bacteria Shrinks Tumors

August 14, 2014 3:00 pm | News | Comments

A modified version of the Clostridium novyi (C. novyi-NT) bacterium can produce a strong and precisely targeted anti-tumor response in rats, dogs and now humans, according to a new report. Read more...              

TOPICS:

Liberia Gets ZMapp, Ponders Who Should Get It

August 14, 2014 2:50 pm | by Jonathan Paye-Layleh and Sarah DiLorenzo | News | Comments

Liberian officials faced a difficult choice Thursday: deciding which handful of Ebola patients will receive an experimental drug that could prove life-saving, ineffective or even harmful. Read more...               

TOPICS:

Breaking News: NewLink Genetics to Test Ebola Vaccine

August 14, 2014 12:48 pm | by Tom Murphy, AP Business Writer | News | Comments

An Iowa drug developer is preparing to test a possible Ebola vaccine in humans, as scientists race to develop ways to prevent or fight a virus that has killed more than 1,000 people in a West African outbreak and for which there is no proven treatment or vaccine. Read more...

TOPICS:

Post-EMA Approval Studies for Agitation Drug Progressing

August 14, 2014 11:08 am | News | Comments

Alexza Pharmaceuticals Inc. provided an update on its European Medicines Agency (EMA) post-approval studies for Adasuve inhalation powder, pre-dispensed (loxapine), of which two have been completed and the data submitted to the EMA. Read more...

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading